GlassScriptPhysician profile
Jory L Sturdevant
NPI 1255094116
$1,230.81
in general payments reported to CMS, 2019-2025
21 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $488 · 2024: $547 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,230.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $308.68 | 2023-2025 | |
| Pfizer INC. | $163.68 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $133.23 | 2024 | Airsupra, Farxiga |
| Astellas Pharma US INC | $72.49 | 2023-2024 | Veozah |
| Novo Nordisk INC | $70.93 | 2023-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $69.76 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $61.38 | 2023-2024 | Gardasil 9, Gardasil, Vaxelis |
| Exact Sciences Corporation | $47.46 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $44.02 | 2023-2024 | Abilify Maintena, Rexulti |
| Phathom Pharmaceuticals, INC. | $42.05 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.47 | 2023-2024 | Synjardy, Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $31.52 | 2023-2024 | |
| Dynavax Technologies Corporation | $20.26 | 2024 | Heplisav-B |
| Baxter Healthcare | $20.25 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Mylan Specialty L.P. | $19.74 | 2024 | Yupelri |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $17.26 | 2024 | |
| Amgen INC. | $15.35 | 2024 | Prolia, Evenity |
| Harmony Biosciences LLC | $14.83 | 2024 | |
| Xeris Pharmaceuticals, INC. | $14.68 | 2024 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $13.88 | 2025 | Shingrix |
| Idorsia Pharmaceuticals US INC | $12.89 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jory Sturdevant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.